Description
Exos 25 mg Pharmacom Labs — exemestane from Pharmacom Labs at 25 mg. Steroidal suicide aromatase inhibitor — irreversible enzyme binding produces smoother tail-off on discontinuation than competitive AIs.
Key Benefits
- Suicidal (irreversible) aromatase inhibitor — different mechanism to anastrozole
- Mildly anabolic in its own right — pleasant AI for cycle use
- Does not tank lipids as aggressively as anastrozole
- Dose 12.5–25 mg daily or EOD on cycle
- Clean alternative to anastrozole when joint dryness is an issue
- Each unit dosed at 25 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 12.5–25 mg every other day or daily on-cycle. Dose by bloodwork. Gyno rescue: 25 mg/day for 2 weeks. Easier on lipids than anastrozole.
How It Works
Steroidal, irreversible aromatase inhibitor. Binds aromatase and permanently inactivates it (suicide inhibition) — new enzyme must be synthesised for activity to resume. Mild anabolic effect in its own right due to androgenic metabolites.
Pharmacokinetics
Plasma half-life approximately 27 hours. Daily or EOD dosing. Steady-state 5 days.
Potential Side Effects
Crashed E2 risk same as other AIs. Lipid impact milder than anastrozole. Mild androgenic side-activity possible at higher doses.
Cycle & Stacking Guide
Alternative to anastrozole on-cycle. 12.5 mg EOD for test E 400–500 mg/week. Popular with users who experience joint dryness on anastrozole.
Manufacturer Notes
Pharmacom Labs operates from EU-registered facilities with in-house HPLC verification. Every batch ships with a unique code on the label — scannable at pharmacom-labs.com to confirm authenticity before the vial ever leaves the box.
Storage & Handling
Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.